InfuSystem execs to join ROTH healthcare conference

Accepted by SEC EDGAR 09/25/2025 - 04:26 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

InfuSystem Holdings, Inc. filed a current report to share that its President and Chief Executive Officer, Carrie Lachance, and its Chief Financial Officer, Barry Steele, will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025. The participation was announced in a press release dated September 25, 2025, which is included as Exhibit 99.1 and furnished under Regulation FD, meaning it is provided for information purposes and is not treated as filed for liability purposes. The report also includes an Inline XBRL cover page data file as Exhibit 104.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did InfuSystem Holdings, Inc. (INFU) announce in this 8-K?

InfuSystem Holdings, Inc. announced that its President and CEO, Carrie Lachance, and its CFO, Barry Steele, will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025.

When was the InfuSystem (INFU) conference participation press release issued?

The press release regarding InfuSystem's participation in the 4th Annual ROTH Healthcare Opportunities Conference was dated September 25, 2025 and is furnished as Exhibit 99.1.

Which InfuSystem executives will attend the 4th Annual ROTH Healthcare Opportunities Conference?

Carrie Lachance, President and Chief Executive Officer, and Barry Steele, Chief Financial Officer of InfuSystem Holdings, Inc., are scheduled to participate in the conference.

How is the InfuSystem (INFU) press release treated under SEC rules?

The press release furnished as Exhibit 99.1 is provided under Item 7.01 Regulation FD Disclosure and is expressly stated as furnished, not filed, so it is not subject to Section 18 liability and is not incorporated by reference into other securities law filings.

What exhibits are included with this InfuSystem 8-K filing?

The filing includes Exhibit 99.1, a press release dated September 25, 2025, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.

Who signed this InfuSystem (INFU) 8-K report?

The report was signed on behalf of InfuSystem Holdings, Inc. by Barry Steele, Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001337013false00013370132025-09-252025-09-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): September 25, 2025

___________________________________

InfuSystem Holdings, Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware (State or other jurisdiction of incorporation or organization)			001-35020 (Commission File Number)			20-3341405 (I.R.S. Employer Identification Number)
3851 West Hamlin Road Rochester Hills, Michigan 48309
(Address of principal executive offices) (Zip Code)
(248) 291-1210
(Registrant's telephone number, including area code)
			Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class			Trading Symbol(s)			Name of Each Exchange on which Registered
Common Stock, par value $.0001 per share			INFU			NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 - Regulation FD Disclosure

On September 25, 2025, InfuSystem Holdings, Inc. (the “Company”) issued a press release announcing that Carrie Lachance, President and Chief Executive Officer, and Barry Steele, Chief Financial Officer, will participate at 4th Annual ROTH Healthcare Opportunities Conference on Thursday, October 9, 2025. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Item 7.01 — “Regulation FD Disclosure” of this Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

Exhibit No.						Description
99.1						Press Release of InfuSystem Holdings, Inc. dated September 25, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFUSYSTEM HOLDINGS, INC.
By:			/s/ Barry Steele
			Barry Steele
			Chief Financial Officer

Dated: September 25, 2025